What Is an Epidural Steroid Injection? How It Works and When It Falls Short

An epidural steroid injection (ESI) is a minimally invasive procedure that delivers corticosteroid medication directly into the epidural space of the spine to reduce inflammation and temporarily relieve pain caused by compressed or irritated nerve roots. ESIs are widely used in non-surgical spine treatment but carry important limitations that patients must understand before choosing this path as a long-term solution.

If you are living with chronic low back pain or radiating leg pain from conditions like herniated discs or spinal stenosis, your doctor has likely mentioned epidural steroid injections. They are one of the most frequently performed interventional pain procedures in the United States—yet a growing body of evidence raises serious questions about their effectiveness, especially for long-term relief. Understanding what ESIs actually do, how they work mechanically, and when they fall short is essential for anyone exploring spinal fusion alternatives or trying to avoid surgery altogether.

This article defines the procedure in plain terms, walks through the mechanism of action, summarizes the evidence on effectiveness, and explains when patients and physicians should look beyond injections for lasting relief.

Definition: What Is an Epidural Steroid Injection?

An epidural steroid injection is a procedure in which a physician uses fluoroscopic (X-ray) or ultrasound guidance to place a needle into the epidural space—the area just outside the membrane (dura mater) surrounding the spinal cord and nerve roots. Once the needle is correctly positioned, the physician injects a mixture typically containing:

• A corticosteroid (such as methylprednisolone, triamcinolone, or dexamethasone) to reduce inflammation
• A local anesthetic (such as lidocaine or bupivacaine) for immediate pain relief
• Sometimes a saline solution to dilute and spread the medication

The epidural space runs the length of the spine. Depending on which spinal region is targeted, injections are classified as cervical (neck), thoracic (mid-back), or lumbar (lower back) epidural steroid injections. The lumbar ESI is by far the most common, given the high prevalence of lower back and leg pain.

Three primary injection approaches are used:

• Interlaminar ESI: The needle is inserted between the vertebral laminae (bony arches) to reach the posterior epidural space.
• Transforaminal ESI (nerve root block): The needle is directed through the foramen (opening) where the nerve exits the spine, placing medication close to the affected nerve root. Many pain specialists consider this the most targeted approach.
• Caudal ESI: The needle enters through the sacral hiatus at the base of the spine—used less frequently, often for lower lumbar and sacral pathology.

How It Works: The Mechanism of an ESI

Spinal pain from conditions such as disc herniation, degenerative disc disease, or spinal stenosis is largely driven by inflammation. When a herniated disc presses against a nearby nerve root, that nerve becomes chemically irritated as well as mechanically compressed. The disc nucleus contains inflammatory proteins—including phospholipase A2 and cytokines—that trigger an inflammatory cascade around the nerve, causing pain, swelling, and altered nerve signaling.

Corticosteroids interrupt this cascade in several ways:

1. Inhibiting phospholipase A2, an enzyme central to the production of prostaglandins and leukotrienes (key inflammatory mediators)
2. Suppressing cytokine production, reducing the chemical environment driving nerve sensitization
3. Stabilizing nerve membranes, which can reduce ectopic (abnormal) electrical discharge from irritated nerves
4. Decreasing capillary permeability, reducing local tissue swelling around compressed structures

The local anesthetic component adds immediate pain relief by temporarily blocking sodium channels in nerve fibers, interrupting pain signal transmission. This effect typically lasts hours; the steroid’s anti-inflammatory action extends the benefit over days to weeks—sometimes longer if the underlying inflammation resolves.

Critically, an ESI does not repair structural damage. It does not heal an annular tear, shrink a disc bulge, or restore disc height. Its action is purely biochemical: dampen inflammation, provide a window of reduced pain during which the body’s own healing processes or physical rehabilitation can occur.

Why ESIs Matter in Non-Surgical Treatment

For patients with acute or subacute radiculopathy—nerve pain radiating from a compressed root—an ESI can provide meaningful short-term relief. This window of reduced pain has real clinical value:

• It allows patients to participate in physical therapy they would otherwise find too painful
• It can help avoid or delay surgery during a period when natural disc resorption is still possible
• It provides diagnostic information: if a targeted nerve root block dramatically reduces pain, it confirms that nerve root as the pain generator

For this reason, ESIs occupy a legitimate place in a stepwise, conservative care approach to spine pain. A pain management doctor often uses ESIs as one tool within a broader treatment protocol that includes activity modification, physical therapy, and patient education.

The problem arises when ESIs are used repeatedly as a stand-alone treatment for chronic spine pain, particularly when the underlying cause is structural disc pathology such as annular tears.

Key Types and Variations

Beyond the three approach types (interlaminar, transforaminal, caudal), ESIs vary by:

• Steroid choice: Particulate steroids (methylprednisolone, triamcinolone) deliver prolonged effect but carry a small risk of vascular occlusion if inadvertently injected into an artery; non-particulate dexamethasone is considered safer for cervical and transforaminal routes.
• Imaging guidance: Fluoroscopy (real-time X-ray) is standard; contrast dye confirms epidural placement. Ultrasound-guided approaches exist but are less precise for spinal injections.
• Number of injections: A course of treatment typically involves one to three injections, spaced two to four weeks apart. Most guidelines recommend no more than three per year due to cumulative steroid exposure risks.
• Combination with physical therapy: Evidence generally supports pairing ESIs with structured rehabilitation rather than using injections alone.

Limitations and When ESI Falls Short

This is the critical information most procedure-focused discussions underemphasize.

The AAFP finding: A systematic review cited by the American Academy of Family Physicians found epidural steroid injections are “not effective” for chronic low back pain alone. While short-term radiculopathy responds in many cases, the evidence for long-term benefit—especially without an accompanying rehabilitation program—is weak.

Duration of relief is limited: Most patients who respond to ESIs experience pain relief lasting weeks to a few months, not permanent resolution. The underlying structural cause—disc pathology, annular disruption, foraminal narrowing—remains unchanged.

Risks of repeated injections include:

• Systemic corticosteroid effects (elevated blood sugar, bone density loss, adrenal suppression) with frequent use
• Rare but serious complications: infection, bleeding, nerve damage, dural puncture (causing “spinal headache”)
• Potential weakening of ligamentous and disc tissue with repeated steroid exposure

ESIs do not address annular tears: A substantial portion of chronic disc pain originates not from nerve compression but from chemical irritation through disrupted annular fibers. Corticosteroids placed in the epidural space do not penetrate the disc to address internal annular disruption. Patients whose pain arises from an annular tear—rather than a large disc herniation compressing a nerve—are the least likely to benefit.

Roughly 40% of back surgeries do not achieve the patient’s desired outcome, according to published data—yet many patients who fail repeated ESIs are funneled toward surgical options that carry their own limitations. This treatment gap is driving interest in biologic approaches that target the disc itself.

For patients with documented annular tears who have not found lasting relief through injections or conservative care, biologic disc repair options—including intra-annular fibrin injection, which delivers a fibrin sealant directly into the disrupted annulus—represent an emerging non-surgical alternative. In fibrin disc treatment studies, VAS pain scores improved from a mean of 72.4 mm at baseline to 33.0 mm at 104 weeks, with approximately 70% patient satisfaction at two or more years of follow-up. These outcomes contrast sharply with the temporary relief pattern typically seen with ESIs alone.

Related Terms

• Radiculopathy: Pain, numbness, or weakness caused by compression or irritation of a spinal nerve root—the primary indication for ESI.
• Epidural space: The space between the dura mater (the outermost membrane surrounding the spinal cord) and the vertebral canal walls; the target compartment for ESI delivery.
• Corticosteroid: A class of anti-inflammatory steroid hormone (natural or synthetic) that suppresses immune-mediated inflammation.
• Annular tear: A rupture or fissure in the fibrous outer ring of an intervertebral disc, allowing disc material or inflammatory proteins to contact nearby nerves.
• Transforaminal injection: A targeted ESI variant directing medication to the specific nerve root foramen—considered more precise than interlaminar approaches for unilateral radiculopathy.
• Intra-annular fibrin injection: A biologic annular tear repair technique delivering a fibrin sealant directly into the disrupted disc; classified as a non-surgical alternative for patients with discogenic pain.
• Discogenic pain: Pain originating within the disc itself—often from annular disruption—rather than from nerve root compression.

Common Misconceptions

Misconception 1: “An ESI will fix my herniated disc.”
An ESI reduces inflammation around a herniated disc but does not repair or resorb the disc. The structural abnormality remains unless the body resorbs the disc material over time (which does occur naturally in many cases) or surgical/biologic intervention addresses it.

Misconception 2: “If one injection helped a little, more injections will help more.”
Diminishing returns are common. The first injection in a series often produces the greatest benefit. Repeated injections rarely produce additive relief and increase cumulative steroid exposure risks.

Misconception 3: “ESIs are the non-surgical option.”
ESIs are one non-surgical option—specifically, an interventional pain management tool. Other approaches including physical therapy, chiropractic care, traction, activity modification, biologic disc repair, and neuromodulation also qualify as non-surgical. Calling ESIs “the” non-surgical solution incorrectly limits patients’ view of their options.

Misconception 4: “ESIs are always covered by insurance and low-risk.”
Coverage varies by payer and clinical indication. While serious complications are uncommon, they are not negligible—infection, hematoma, and nerve injury occur rarely but do occur. Repeat injections also carry systemic risks that are often not explained at the time of consent.

Frequently Asked Questions

How long does an epidural steroid injection last?

Relief duration varies widely. Some patients experience benefit for a few days; others report relief lasting three to six months. The average response is typically measured in weeks to a couple of months for radiculopathy. There is no reliable way to predict duration for an individual patient in advance. Patients whose pain returns quickly after each injection—or who require injections more than twice a year—warrant evaluation for underlying causes that ESIs cannot address.

How many epidural steroid injections can I have per year?

Most clinical guidelines recommend no more than three injections in a given spinal region per year, and some specialists prefer to limit injections further based on individual response and systemic health. Exceeding this frequency increases the risk of corticosteroid-related side effects including bone density loss, elevated blood glucose, and potential weakening of surrounding soft tissues. There is no defined lifetime maximum, but the cumulative systemic burden of steroids should factor into any decision about ongoing injection therapy.

Are epidural steroid injections effective for chronic low back pain?

The evidence for chronic low back pain without a radicular component is weak. An AAFP-cited systematic review found ESIs are “not effective” for chronic LBP as a stand-alone treatment. The strongest evidence for ESI benefit is in patients with acute or subacute radiculopathy—leg or arm pain caused by a herniated disc pressing on a nerve root. Patients with axial (non-radiating) chronic back pain from degenerative disc disease or annular tears derive limited benefit from epidural corticosteroids.

What are the risks of an epidural steroid injection?

Common, mild risks include temporary pain at the injection site, mild headache, and a brief flare of spine pain in the first day or two. Less common risks include dural puncture (which can cause a positional headache that resolves with rest or a blood patch procedure), temporary elevation in blood sugar (particularly relevant for diabetic patients), and facial flushing. Rare but serious risks include epidural hematoma, epidural abscess, nerve injury, and—in cervical transforaminal injections with particulate steroids—catastrophic vascular events. These rare complications underscore the importance of using imaging guidance and an experienced proceduralist.

When should I consider alternatives to epidural steroid injections?

Consider alternatives when: you have had three or more injection series with diminishing returns; your pain is primarily axial (not radiating) and diagnostic imaging reveals annular disruption rather than disc herniation; you have contraindications to corticosteroids (uncontrolled diabetes, active infection, recent fracture); or your symptoms have persisted beyond twelve months without structural improvement. Emerging non-surgical options—including biologic disc repair approaches such as intra-annular fibrin injection—specifically target the disc pathology that ESIs cannot reach, and warrant discussion with a spine specialist experienced in the full range of non-surgical options.

Sources & Further Reading

1. Staal JB, et al. “Injection therapy for subacute and chronic low back pain.” Cochrane Database of Systematic Reviews. 2008. (Referenced in AAFP clinical guidance finding ESIs “not effective” for chronic LBP alone.)
2. Chou R, et al. “Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society.” Annals of Internal Medicine. 2007;147(7):478–491.
3. Manchikanti L, et al. “Epidural Injections for Lumbar Radiculopathy and Spinal Stenosis: A Comparative Systematic Review and Meta-Analysis.” Pain Physician. 2016;19:E365–E410.
4. Friedly JL, et al. “A Randomized Trial of Epidural Glucocorticoid Injections for Spinal Stenosis.” New England Journal of Medicine. 2014;371:11–21.
5. Kennedy DJ, et al. “Comparative effectiveness of lumbar transforaminal epidural steroid injections with particulate versus nonparticulate corticosteroids for lumbar radicular pain due to intervertebral disc herniation.” PM&R. 2014;6(9):790–796.
6. Deyo RA, Mirza SK. “Trends and variations in the use of spine surgery.” Clinical Orthopaedics and Related Research. 2006;443:139–146. (Source for the ~40% failed surgery outcome data.)
7. Pauza KJ, et al. “A randomized, placebo-controlled trial of intradiscal electrothermal therapy for the treatment of discogenic low back pain.” Spine Journal. 2004;4(1):27–35. (Background on discogenic pain mechanisms.)

Ready to explore non-surgical options for your back pain? Schedule your consultation with ValorSpine today.